Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pirfenidone, an Antifibrotic and Antiinflammatory Drug for Treatment of Patients With Cirrhosis Due to Hepatitis C Virus. Phase II/III Study

NCT02161952 is registered in ClinicalTrials.gov with University of Guadalajara as lead sponsor.

NCT NCT02161952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02161952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pirfenidone, an Antifibrotic and Antiinflammatory Drug for Treatment of Patients With Cirrhosis Due to Hepatitis C Virus. Phase II/III Study
Lead sponsor
University of Guadalajara
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2005
Completion date
August 31, 2007
Enrollment
150 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

fibrosis, hepatitis c chronic